These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 33132228)

  • 1. Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source　- Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial.
    Toyoda K; Uchiyama S; Hagihara Y; Kuwashiro T; Mori T; Kamiyama K; Urano Y; Taniguchi A; Nozaki K; Cronin L; Grauer C; Brueckmann M; Diener HC
    Circ J; 2020 Nov; 84(12):2286-2295. PubMed ID: 33132228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).
    Diener HC; Easton JD; Granger CB; Cronin L; Duffy C; Cotton D; Brueckmann M; Sacco RL;
    Int J Stroke; 2015 Dec; 10(8):1309-12. PubMed ID: 26420134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis.
    Uchiyama S; Toyoda K; Lee BC; Liou CW; Wong LKS; Grauer C; Brueckmann M; Taniguchi A; Urano Y; Easton JD;
    Stroke; 2021 Mar; 52(3):1069-1073. PubMed ID: 33588594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.
    Diener HC; Sacco RL; Easton JD; Granger CB; Bar M; Bernstein RA; Brainin M; Brueckmann M; Cronin L; Donnan G; Gdovinová Z; Grauer C; Kleine E; Kleinig TJ; Lyrer P; Martins S; Meyerhoff J; Milling T; Pfeilschifter W; Poli S; Reif M; Rose DZ; Šaňák D; Schäbitz WR
    Stroke; 2020 Jun; 51(6):1758-1765. PubMed ID: 32404035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
    Diener HC; Chutinet A; Easton JD; Granger CB; Kleine E; Marquardt L; Meyerhoff J; Zini A; Sacco RL
    Stroke; 2021 Mar; 52(3):1065-1068. PubMed ID: 33504190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial.
    Del Brutto VJ; Diener HC; Easton JD; Granger CB; Cronin L; Kleine E; Grauer C; Brueckmann M; Toyoda K; Schellinger PD; Lyrer P; Molina CA; Chutinet A; Bladin CF; Estol CJ; Sacco RL
    J Am Heart Assoc; 2022 Jun; 11(11):e023545. PubMed ID: 35656979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
    Diener HC; Sacco RL; Easton JD; Granger CB; Bernstein RA; Uchiyama S; Kreuzer J; Cronin L; Cotton D; Grauer C; Brueckmann M; Chernyatina M; Donnan G; Ferro JM; Grond M; Kallmünzer B; Krupinski J; Lee BC; Lemmens R; Masjuan J; Odinak M; Saver JL; Schellinger PD; Toni D; Toyoda K;
    N Engl J Med; 2019 May; 380(20):1906-1917. PubMed ID: 31091372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial.
    Bahit MC; Sacco RL; Easton JD; Meyerhoff J; Cronin L; Kleine E; Grauer C; Brueckmann M; Diener HC; Lopes RD; Brainin M; Lyrer P; Wachter R; Segura T; Granger CB;
    Circulation; 2021 Nov; 144(22):1738-1746. PubMed ID: 34649459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
    Merkler AE; Pearce LA; Kasner SE; Shoamanesh A; Birnbaum LA; Kamel H; Sheth KN; Sharma R
    JAMA Neurol; 2021 Dec; 78(12):1454-1460. PubMed ID: 34694346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial.
    Veltkamp R; Pearce LA; Korompoki E; Sharma M; Kasner SE; Toni D; Ameriso SF; Mundl H; Tatlisumak T; Hankey GJ; Lindgren A; Berkowitz SD; Arauz A; Ozturk S; Muir KW; Chamorro Á; Perera K; Shuaib A; Rudilosso S; Shoamanesh A; Connolly SJ; Hart RG
    JAMA Neurol; 2020 Oct; 77(10):1233-1240. PubMed ID: 32628266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
    Shoamanesh A; Hart RG; Connolly SJ; Kasner SE; Smith EE; Martí-Fàbregas J; Liu YY; Uchiyama S; Mikulik R; Veltkamp R; O'Donnell MJ; Ntaios G; Muir KW; Field TS; Santo GC; Olavarria V; Mundl H; Lutsep H; Berkowitz SD; Sharma M
    JAMA Neurol; 2021 Jan; 78(1):11-20. PubMed ID: 33074284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation.
    Witte KK; Tsivgoulis G; Reynolds MR; Tsintzos SI; Eggington S; Ismyrloglou E; Lyon J; Huynh M; Egea M; de Brouwer B; Ziegler PD; Franco N; Joglekar R; Rosemas SC; Liu S; Thijs V
    BMC Cardiovasc Disord; 2021 Mar; 21(1):160. PubMed ID: 33789592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial.
    Hart RG; Veltkamp RC; Sheridan P; Sharma M; Kasner SE; Bangdiwala SI; Ntaios G; Shoamanesh A; Ameriso SF; Toni D; Czlonkowska A; Lindgren A; Hankey GJ; Perera KS; Shuaib A; Coutts SB; Gagliardi RJ; Berkowitz SD; Mundl H; Peters G; Connolly SJ;
    J Stroke Cerebrovasc Dis; 2019 Aug; 28(8):2273-2279. PubMed ID: 31160218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Embolic Stroke of Undetermined Source: Gateway to a New Stroke Entity?
    Schäbitz WR; Köhrmann M; Schellinger PD; Minnerup J; Fisher M
    Am J Med; 2020 Jul; 133(7):795-801. PubMed ID: 32247819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
    Kasner SE; Swaminathan B; Lavados P; Sharma M; Muir K; Veltkamp R; Ameriso SF; Endres M; Lutsep H; Messé SR; Spence JD; Nedeltechev K; Perera K; Santo G; Olavarria V; Lindgren A; Bangdiwala S; Shoamanesh A; Berkowitz SD; Mundl H; Connolly SJ; Hart RG;
    Lancet Neurol; 2018 Dec; 17(12):1053-1060. PubMed ID: 30274772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Embolic strokes of undetermined source: theoretical construct or useful clinical tool?
    Tsivgoulis G; Katsanos AH; Köhrmann M; Caso V; Lemmens R; Tsioufis K; Paraskevas GP; Bornstein NM; Schellinger PD; Alexandrov AV; Krogias C
    Ther Adv Neurol Disord; 2019; 12():1756286419851381. PubMed ID: 31205494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban versus Aspirin for Embolic Stroke of Undetermined Source.
    Geisler T; Keller T; Martus P; Poli K; Serna-Higuita LM; Schreieck J; Gawaz M; Tünnerhoff J; Bombach P; Nägele T; Klose U; Aidery P; Groga-Bada P; Kraft A; Hoffmann F; Hobohm C; Naupold K; Niehaus L; Wolf M; Bäzner H; Liman J; Wachter R; Kimmig H; Jung W; Huber R; Feurer R; Lindner A; Althaus K; Bode FJ; Petzold GC; Nguyen TN; Mac Grory B; Schrag M; Purrucker JC; Zuern CS; Ziemann U; Poli S;
    NEJM Evid; 2024 Jan; 3(1):EVIDoa2300235. PubMed ID: 38320511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy.
    Sharma M; Smith EE; Pearce LA; Perera KS; Kasner SE; Yoon BW; Ameriso SF; Puig J; Damgaard D; Fiebach JB; Muir KW; Veltkamp RC; Toni DS; Shamalov N; Gagliardi RJ; Mikulik R; Engelter ST; Bereczki D; O'Donnell MJ; Saad F; Shoamanesh A; Berkowitz SD; Mundl H; Hart RG;
    Int J Stroke; 2022 Aug; 17(7):799-805. PubMed ID: 34791941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial.
    Hart RG; Sharma M; Mundl H; Shoamanesh A; Kasner SE; Berkowitz SD; Pare G; Kirsch B; Pogue J; Pater C; Peters G; Davalos A; Lang W; Wang Y; Wang Y; Cunha L; Eckstein J; Tatlisumak T; Shamalov N; Mikulik R; Lavados P; Hankey GJ; Czlonkowska A; Toni D; Ameriso SF; Gagliardi RJ; Amarenco P; Bereczki D; Uchiyama S; Lindgren A; Endres M; Brouns R; Yoon BW; Ntaios G; Veltkamp R; Muir KW; Ozturk S; Arauz A; Bornstein N; Bryer A; O'Donnell MJ; Weitz J; Peacock F; Themeles E; Connolly SJ
    Eur Stroke J; 2016 Sep; 1(3):146-154. PubMed ID: 31008276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Embolic Stroke of Undetermined Source: JACC Review Topic of the Week.
    Ntaios G
    J Am Coll Cardiol; 2020 Jan; 75(3):333-340. PubMed ID: 31976872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.